Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of varicella or residence int he US for 30 years~* For Arms C and D - prior live zoster vaccine at least 5 years previously~* For Arms A and B - Age 50-59 or 70-85~* For Arms C and D - Age 70-85~* For women of childbearing potential, a negative pregnancy test and agreement to use adequate contraception from 30 days before until 3 months after the last dose of any study vaccine~Exclusion Criteria:~* History of herpes zoster~* For Arms A and B - prior live zoster vaccine~* Immune compromising illness or therapies or chronic illness~* Allergy to previous herpes zoster vaccine~* Other investigational drugs or vaccines within the past 6 months before the study and until last visit~* Blood products for 3 months prior to or planned during the study~* Concomitant non-topical antiviral therapy within 3 days prior to and 7 days after vaccination.~* Vaccines within 2 weeks (inactive vaccine) or 4 weeks (live vaccine) prior to the study until 30 days after any dose of either vaccine.~* Pregnancy or breast-feeding~* Current drug addiction or alcoholism.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- A - Live zoster vaccine (Type: ACTIVE_COMPARATOR): No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)
- B - recombinant zoster vaccine (Type: ACTIVE_COMPARATOR): No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
- C - Live zoster vaccine (Type: ACTIVE_COMPARATOR): One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)
- D - recombinant zoster vaccine (Type: ACTIVE_COMPARATOR): One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)

Based on this trial design, predict the completion outcome and termination type (if applicable).